Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
UN chief applauds formation of transitional council in Haiti
UNITED NATIONS, April 13 (Xinhua) -- UN Secretary-General Antonio Guterres expressed his support on2024-05-01Mississippi lawmakers quietly kill bills to restrict legal recognition of transgender people
JACKSON, Miss. (AP) — Mississippi’s Republican-led Legislature will not take final votes on two bill2024-05-01Heat rule rookie forward Jaime Jaquez Jr. out of Game 5 vs. Celtics with hip injury
MIAMI (AP) — The Miami Heat will be without yet another starter when they face an elimination game i2024-05-01- MIAMI (AP) — Colorado Rockies highly-rated outfielder Jordan Beck was brought up from the minor leag2024-05-01
Rescue underway after earthquake hits Syria
Rescuers work around a damaged building after a powerful earthquake in the al-Arbaeen neighborhood i2024-05-01Italy's League party picks a provocative candidate for European Parliament election
ROME (AP) — He was fired by the defense minister after writing a book deemed offensive to women, gay2024-05-01
atest comment